Scientists at McMaster University have discovered several new biomarkers from a single drop of blood that could allow earlier and more definitive detection of cystic fibrosis (CF), a genetic disease which strikes both children and adults, causing chronic problems with the digestive system and the lungs.
The findings, published online in the Journal of Proteome Research, are significant because current newborn screening methods are not accurate enough to identify the disorder in the population, which can manifest itself in many different ways, requiring additional testing and causing further stress for anxious parents.
“The earlier CF is detected, the earlier it can be managed and treated, which means better health outcomes for affected infants, including their future growth and development,” says Philip Britz-McKibbin, lead author of the study and a professor in McMaster’s Department of Chemistry & Chemical Biology, who conducted the research with graduate student Alicia DiBattista, now a postdoctoral fellow at Newborn Screening Ontario (NSO).
A tiny amount of blood is drawn from the heel of all babies as part of universal newborn screening programs that test for many rare yet treatable diseases since babies usually have no signs of disease at birth, including CF.
In the case of CF, infants are screened for a pancreatic enzyme and then a panel of disease-causing genetic mutations associated with CF. However, further testing to confirm or rule out the disease finds that most babies who screen-positive do not actually have the disease. These babies are later found to be “healthy carriers” or their results are deemed to be “false positives”.
With this in mind, researchers set out to determine whether they could discover chemical signatures in a dried blood spot that could better distinguish infants who have CF from those who do not.
Using less than a single drop of blood stored at NSO at CHEO, a pediatric health and research centre in Ottawa, researchers analyzed and compared samples from infants confirmed to have CF with the samples of both healthy and screen positive infants. They found several new compounds as well as simple amino acids directly related to affected infants with CF who otherwise have no symptoms and normal birth weight.
“These biomarkers provide new insights into the disease process early in life before symptoms are fully apparent,” says Britz-McKibbin. “Moreover, these compounds can be analyzed by mass spectrometry at incremental costs since it is already used for testing many other genetic diseases at newborn screening facilities around the world”
“Ontario started screening for Cystic Fibrosis in April 2007, and since that time over 400 children have already benefited from early recognition and early treatment. But for every one of these children, about 10 have had a false-positive result. We want to get this number down and are very hopeful that the new biomarkers discovered by this research project will help us do exactly that,” says Pranesh Chakraborty, medical director of NSO at CHEO.
In Canada, life expectancy rates have risen dramatically with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition, lung transplants. The advent of universal newborn screening programs for CF will likely further improve the quality of life of affected patients.
“We know that early detection can have significant benefits for people living with cystic fibrosis,” said Dr. John Wallenburg, chief scientific officer at Cystic Fibrosis Canada. “The current screening methodologies capture a broad swathe of families that then need further testing to narrow down those that are true positives. The anxiety and distress that such further testing can needlessly cause families was a major concern that slowed the adoption of newborn screening in some jurisdictions. Dr. Britz-McKibbin’s data provide insights for more specific newborn screening, as well as early manifestations of the disease.”
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Medicare Coverage for Cystic Fibrosis: Testing, Management, and Treatmentson January 12, 2021 at 1:31 pm
Medicare covers the testing, treatment, and care you need for cystic fibrosis. Find out exactly what's covered by the different parts of Medicare.
- Vertex CEO says it has the ‘financial firepower’ to make more dealson January 11, 2021 at 3:58 pm
Vertex Pharmaceuticals is looking to acquire “mid- and late-stage assets” to bolster its current research pipeline, CEO Reshma Kewalramani said Monday at the virtual J.P. Morgan Healthcare Conference.
- Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugson January 11, 2021 at 8:40 am
With its balance sheet growing with cash from its cystic fibrosis drugs, Vertex has the “financial firepower” to consider deals, CEO says.
- Benefits of 'transformational' cystic fibrosis drug highlighted in new reviewon January 11, 2021 at 6:22 am
A new systematic review by University of Liverpool researchers highlights the positive impact that triple-combination therapy has on the wellbeing of people with Cystic Fibrosis (CF).
- Machine learning comes of age in cystic fibrosison January 8, 2021 at 7:18 am
World-leading AI technology developed by the Cambridge Centre for AI in Medicine and their colleagues offers a glimpse of the future of precision medicine, and unprecedented predictive power to ...
- Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in ...on January 7, 2021 at 10:45 pm
MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- -- Completed ...
- Felix Biotechnology announces initiation of the CYPHY Phase 1/2 study at Yale for its lead asset targeting P. aeruginosa infectionson January 7, 2021 at 1:04 pm
Felix Biotechnology today announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University ...
- Supermarket worker awarded compensation after foot injury led to aggravation of cystic fibrosison January 4, 2021 at 9:41 pm
A worker who suffers cystic fibrosis has been awarded compensation for a lung transplant he needed as a result of a foot injury while at work, despite not telling his employer of his long term illness ...
- Dallas respiratory therapist commits to helping patients, even as cystic fibrosis puts her at riskon January 3, 2021 at 10:00 am
When the coronavirus pandemic began, everyone told Breanna Pierce what she should do. Her doctors suggested and her family urged: Take a break ...
- Global Cystic Fibrosis Therapeutics Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecaston December 31, 2020 at 12:53 pm
The "Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global cystic ...
via Bing News